Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 1025820, 16 pages
Research Article

Transcriptome Profiling of IL-17A Preactivated Mesenchymal Stem Cells: A Comparative Study to Unmodified and IFN-γ Modified Mesenchymal Stem Cells

1School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia
2Centre for Clinical and Experimental Transplantation, Royal Adelaide Hospital, Adelaide, SA, Australia
3Transplantation Immunology Group, Garvan Institute of Medical Research, Sydney, NSW, Australia
4South Australian Health and Medical Research Institute, Adelaide, SA, Australia
5Mesenchymal Stem Cell Laboratory, School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia
6Central Northern Adelaide Renal Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia

Correspondence should be addressed to Kisha Nandini Sivanathan; ua.ude.edialeda@nahtanavis.ahsik

Received 21 September 2016; Accepted 20 December 2016; Published 15 February 2017

Academic Editor: Thomas Ichim

Copyright © 2017 Kisha Nandini Sivanathan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Human mesenchymal stem cells pretreatment with IL-17A (MSC-17) potently enhances T cell immunosuppression but not their immunogenicity, in addition to avidly promoting the induction of suppressive regulatory T cells. The aim of this study was to identify potential mechanisms by which human MSC-17 mediate their superior immunomodulatory function. Untreated-MSC (UT-MSC), IFN-γ treated MSC (MSC-γ), and MSC-17 were assessed for their gene expression profile by microarray. Significantly regulated genes were identified for their biological functions (Database for Annotation, Visualisation and Integrated Discovery, DAVID). Microarray analyses identified 1278 differentially regulated genes between MSC-γ and UT-MSC and 67 genes between MSC-17 and UT-MSC. MSC-γ were enriched for genes involved in immune response, antigen processing and presentation, humoral response, and complement activation, consistent with increased MSC-γ immunogenicity. MSC-17 genes were associated with chemotaxis response, which may be involved in T cell recruitment for MSC-17 immunosuppression. MMP1, MMP13, and CXCL6 were highly and specifically expressed in MSC-17, which was further validated by real-time PCR. Thus, MMPs and chemokines may play a key role in mediating MSC-17 superior immunomodulatory function. MSC-17 represent a potential cellular therapy to suppress immunological T cell responses mediated by expression of an array of immunoregulatory molecules.